Dr. Eugenia Girda, MD
Claim this profileRutgers Cancer Institute of New Jersey
Studies Ovarian Cancer
Studies Cancer
16 reported clinical trials
31 drugs studied
Area of expertise
1Ovarian Cancer
KRAS positive
BRCA1 positive
BRAF positive
2Cancer
KRAS positive
BRAF positive
NRAS positive
Affiliated Hospitals
Clinical Trials Eugenia Girda, MD is currently running
ZN-c3
for Uterine Cancer
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Recruiting1 award Phase 26 criteria
Ipatasertib + Chemotherapy
for Cancer
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with PTEN and AKT genetic changes could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.
Recruiting1 award Phase 2
More about Eugenia Girda, MD
Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Eugenia Girda, MD has experience with
- Paclitaxel
- Carboplatin
- Pembrolizumab
- Atezolizumab
- Bevacizumab
- Nivolumab
Breakdown of trials Eugenia Girda, MD has run
Ovarian Cancer
Cancer
Solid Tumors
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eugenia Girda, MD specialize in?
Eugenia Girda, MD focuses on Ovarian Cancer and Cancer. In particular, much of their work with Ovarian Cancer has involved KRAS positive patients, or patients who are BRCA1 positive.
Is Eugenia Girda, MD currently recruiting for clinical trials?
Yes, Eugenia Girda, MD is currently recruiting for 6 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Eugenia Girda, MD has studied deeply?
Yes, Eugenia Girda, MD has studied treatments such as Paclitaxel, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Eugenia Girda, MD?
Apply for one of the trials that Eugenia Girda, MD is conducting.
What is the office address of Eugenia Girda, MD?
The office of Eugenia Girda, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.